Ibrutinib and rituximab trigger 95 percent response rate among CLL patients

Nearly all of the high-risk chronic lymphocytic leukemia patients in a phase II clinical trial responded to treatment with the targeted therapy ibrutinib and the antibody rituximab, researchers reported at the 55th Annual Meeting of the American Society of Hematology. Read more here.